<DOC>
	<DOCNO>NCT01503541</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow blood patient cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This research trial study biomarkers sample patient acute myeloid leukemia treat standard chemotherapy without gemtuzumab ozogamicin .</brief_summary>
	<brief_title>S9031-9333-0106-0112-A Study Biomarkers Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With Without Gemtuzumab Ozogamicin</brief_title>
	<detailed_description>OBJECTIVES : - To determine whether measure biomarkers less-differentiated acute myeloid leukemia ( AML ) blast significantly improve predictive accuracy predict clinical outcome patient receive induction/consolidation chemotherapy without gemtuzumab ozogamicin . - To develop validate novel predictive biomarker model predict clinical outcome AML patient receive induction/consolidation chemotherapy without gemtuzumab ozogamicin . OUTLINE : DNA RNA extract archive bone marrow peripheral blood sample analyze genomic mutation ( CEBPA , FLT3 , IDH1/2 , KIT , NPM1 , RUNX1 , TP53 , WT1 ) transcriptional biomarkers ( BAALC , CCNA1 , CD34 , CEBPA , ERG , EVI1 , FLT3 , IL3RA , MCL1 [ two splice variant ] , MN1 , RUNX1 , WT1 ) PCR real-time PCR . Data analyze Gene Scan software .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pretreatment bone marrow ( BM ) peripheral blood ( PB ) sample obtain Southwest Oncology Group ( SWOG ) Leukemia Repository adult patient enrol SWOG9031 , SWOG9333 , SWOGS0106 , SWOGS0112 Samples restrict patient study least 3 vial remain material SWOG Leukemia Repository vial contain least 1.5 x 10^7 cells/vial Samples patient receive standard induction cytarabine ( ARA ) /daunorubicin hydrochloride ( DNR ) addition gemtuzumab ozogamicin ( MylotargÂ® ) one arm S0106 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia</keyword>
</DOC>